Caregiver adverse childhood experiences were related to pediatric health outcomes, such as antibiotic prescribing and time to first infection-related clinical encounter.
FDA approves new oral antibiotic for uncomplicated urinary tract infections in women with limited treatment options. Orylnvah shows superior response rates ...
Not much went right for Spero Therapeutics’ SPR720 in its phase 2a trial. | Not much went right for Spero Therapeutics’ SPR720 in its phase 2a trial. An interim analysis revealed a double blow to the ...
The FDA has approved Orlynvah, a new oral treatment for uncomplicated urinary tract infections (UTIs) in women who have limited options for effective antibiotic therapy.